CN1130196C - 通过无冷冻的干燥方法进行的稳定生物材料的制剂和方法 - Google Patents

通过无冷冻的干燥方法进行的稳定生物材料的制剂和方法 Download PDF

Info

Publication number
CN1130196C
CN1130196C CN96199329A CN96199329A CN1130196C CN 1130196 C CN1130196 C CN 1130196C CN 96199329 A CN96199329 A CN 96199329A CN 96199329 A CN96199329 A CN 96199329A CN 1130196 C CN1130196 C CN 1130196C
Authority
CN
China
Prior art keywords
drying
derivatives
substances
glass transition
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96199329A
Other languages
English (en)
Chinese (zh)
Other versions
CN1205628A (zh
Inventor
M·马特恩
G·温特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7775640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1130196(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Publication of CN1205628A publication Critical patent/CN1205628A/zh
Application granted granted Critical
Publication of CN1130196C publication Critical patent/CN1130196C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Drying Of Solid Materials (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN96199329A 1995-10-25 1996-10-24 通过无冷冻的干燥方法进行的稳定生物材料的制剂和方法 Expired - Fee Related CN1130196C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539574.3 1995-10-25
DE19539574A DE19539574A1 (de) 1995-10-25 1995-10-25 Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren

Publications (2)

Publication Number Publication Date
CN1205628A CN1205628A (zh) 1999-01-20
CN1130196C true CN1130196C (zh) 2003-12-10

Family

ID=7775640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96199329A Expired - Fee Related CN1130196C (zh) 1995-10-25 1996-10-24 通过无冷冻的干燥方法进行的稳定生物材料的制剂和方法

Country Status (25)

Country Link
US (3) US7172999B2 (de)
EP (1) EP0857060B1 (de)
JP (2) JPH11513700A (de)
KR (1) KR100466670B1 (de)
CN (1) CN1130196C (de)
AT (1) ATE212541T1 (de)
AU (1) AU712489B2 (de)
BR (1) BR9611265A (de)
CA (1) CA2235243C (de)
CZ (1) CZ293456B6 (de)
DE (2) DE19539574A1 (de)
DK (1) DK0857060T3 (de)
ES (1) ES2170274T3 (de)
HU (1) HU222601B1 (de)
IL (1) IL124204A (de)
MX (1) MX9803264A (de)
NO (1) NO324728B1 (de)
NZ (1) NZ320276A (de)
PL (1) PL190657B1 (de)
PT (1) PT857060E (de)
RU (1) RU2191003C2 (de)
SK (1) SK283664B6 (de)
TR (1) TR199800715T2 (de)
WO (1) WO1997015288A2 (de)
ZA (1) ZA968930B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0913178A1 (de) * 1997-11-03 1999-05-06 Boehringer Mannheim Gmbh Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialen mittels Konvektionstrocknung und die erhaltenen Produkte
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
PT1181036E (pt) * 1999-04-09 2008-10-03 Ortho Mcneil Pharm Inc Composições farmacêuticas de eritropoietina
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
AU2000264912A1 (en) * 2000-06-07 2001-12-17 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
CN101352421A (zh) * 2002-01-16 2009-01-28 贝林格尔英格海姆法玛两合公司 一种制备基本上非结晶形式的替米沙坦的方法
KR100556503B1 (ko) * 2002-11-26 2006-03-03 엘지전자 주식회사 건조기의 건조 시간제어 방법
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
CA2560513A1 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8097245B2 (en) 2005-12-28 2012-01-17 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2236520A1 (de) * 2009-03-31 2010-10-06 Leukocare Ag Stabilisierungszusammensetzung für immobilisierte Biomoleküle
WO2010138522A2 (en) * 2009-05-26 2010-12-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
US8834951B2 (en) 2010-01-28 2014-09-16 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CA2806670A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012021783A2 (en) 2010-08-13 2012-02-16 Advanced Bionutrition Corporation Dry storage stabilizing composition for biological materials
CN102408467B (zh) * 2010-09-26 2014-03-05 海口维瑅瑷生物研究院 真空干燥蛋白的方法、制得的蛋白产品和试剂盒
AU2012242565B2 (en) 2011-04-13 2017-05-11 Thermolife International, Llc N-Acetyl Beta Alanine methods of use
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
CN106572650B (zh) 2014-06-10 2021-08-31 生物马特里卡公司 在环境温度下稳定凝血细胞
US9868944B2 (en) * 2014-12-19 2018-01-16 Roche Molecular Systems, Inc. Reaction mixtures
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102567744B1 (ko) * 2015-02-11 2023-08-18 에바 뉴트리션 인크 생존 가능한 대장균을 삽입하기 위한 향상된 건조 기질, 이의 제조 방법 및 용도
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
SG11201804776SA (en) 2015-12-08 2018-07-30 Biomatrica Inc Reduction of erythrocyte sedimentation rate
CN106831466B (zh) * 2016-12-28 2018-05-22 安徽省虹升生物股份有限公司 一种β-丙氨酸的常规储存方法
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
EP3781192A1 (de) * 2018-04-16 2021-02-24 Merck Patent GmbH Zusätze für proteinformulierungen zur verbesserung der thermischen stabilität
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
MX2023000557A (es) * 2020-07-13 2023-02-13 Merck Patent Gmbh Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas.
US12156886B2 (en) 2020-11-12 2024-12-03 Thermolife International, Llc Methods of increasing blood oxygen saturation
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
MX2023009015A (es) 2021-02-11 2023-08-08 Thermolife Int Llc Un metodo para administrar gas de oxido nitrico.
CN114480129A (zh) * 2022-01-13 2022-05-13 力因精准医疗产品（上海）有限公司 一种人粪便保存液及使用方法
KR102913374B1 (ko) * 2022-12-28 2026-01-15 씨제이제일제당 주식회사 발효 제품 제조 방법

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714353A (en) * 1959-08-11 1973-01-30 Upjohn Co THERAPEUTIC COMPOSITIONS COMPRISING A 6 alpha ; 9 alpha -DIFLUORO-11 beta ,17 alpha ,21-TRIHYDROXY-16 alpha -METHYL-1,4-PREGNADIENE-3,20-DIONE AND 21-ACYLATES
US3852461A (en) * 1971-08-04 1974-12-03 Upjohn Co Benzodiapines used as minor tranquilizers
JPS5836954B2 (ja) * 1980-03-31 1983-08-12 栄研化学株式会社 酵素の安定化剤
JPS5967228A (ja) 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4788072A (en) * 1985-08-15 1988-11-29 Toshimitsu Kawamura Method of dehydrating foods
US4808617A (en) 1985-12-18 1989-02-28 Bristol-Myers Company Lyophilized or precipitated cephalosporin zwitterion and salt combination
WO1988006457A1 (fr) * 1987-03-04 1988-09-07 Nippon Hypox Laboratories Incorporated Composition medicinale contenant de l'albumine en tant que support et procede de preparation
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4886742A (en) * 1987-06-15 1989-12-12 Coulter Corporation Enzyme immunoassay for detecting HIV antigens in human sera
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
CA1339071C (en) 1988-08-24 1997-07-29 Koichiro Tsuji Thrombus control agent
JPH0296536A (ja) 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
JP2739584B2 (ja) 1989-01-06 1998-04-15 株式会社ミドリ十字 ウロキナーゼ型プラスミノーゲンアクチベーター乾燥製剤
US5186944A (en) * 1989-02-15 1993-02-16 Eimei Company Ltd. Therapeutic medicament for thrombosis
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
JPH0775519B2 (ja) 1989-10-06 1995-08-16 東洋製罐株式会社 ドライパック包装食品の製造方法
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JPH0813750B2 (ja) 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
US5200399A (en) * 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5217741A (en) 1991-01-25 1993-06-08 Snow Brand Milk Products Co., Ltd. Solution containing whey protein, whey protein gel, whey protein powder and processed food product produced by using the same
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤
DE4141351A1 (de) 1991-12-14 1993-06-17 Basf Ag Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
IT1254359B (it) 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP3168550B2 (ja) * 1992-12-02 2001-05-21 株式会社林原生物化学研究所 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren

Also Published As

Publication number Publication date
RU2191003C2 (ru) 2002-10-20
DE19539574A1 (de) 1997-04-30
DK0857060T3 (da) 2002-05-13
US20070020289A1 (en) 2007-01-25
KR19990067082A (ko) 1999-08-16
AU7298496A (en) 1997-05-15
PT857060E (pt) 2002-07-31
NO981868L (no) 1998-06-25
SK283664B6 (sk) 2003-11-04
WO1997015288A3 (de) 1997-05-29
ZA968930B (en) 1998-04-24
HU222601B1 (hu) 2003-08-28
HUP9901314A3 (en) 2000-02-28
MX9803264A (es) 1998-09-30
CN1205628A (zh) 1999-01-20
NO981868D0 (no) 1998-04-24
US7172999B2 (en) 2007-02-06
BR9611265A (pt) 1999-05-04
ES2170274T3 (es) 2002-08-01
PL326358A1 (en) 1998-09-14
TR199800715T2 (xx) 1998-08-21
JP2007236975A (ja) 2007-09-20
EP0857060B1 (de) 2002-01-30
KR100466670B1 (ko) 2005-09-07
EP0857060A2 (de) 1998-08-12
JPH11513700A (ja) 1999-11-24
US20030059468A1 (en) 2003-03-27
NO324728B1 (no) 2007-12-03
CA2235243A1 (en) 1997-05-01
CA2235243C (en) 2003-04-22
AU712489B2 (en) 1999-11-11
NZ320276A (en) 1999-11-29
CZ117998A3 (cs) 1998-11-11
DE59608684D1 (de) 2002-03-14
CZ293456B6 (cs) 2004-05-12
PL190657B1 (pl) 2005-12-30
SK50998A3 (en) 1998-12-02
WO1997015288A2 (de) 1997-05-01
HUP9901314A2 (hu) 1999-07-28
IL124204A (en) 2001-10-31
US20010055617A1 (en) 2001-12-27
ATE212541T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
CN1130196C (zh) 通过无冷冻的干燥方法进行的稳定生物材料的制剂和方法
JP2007236975A6 (ja) 凍結しない乾燥過程により生物材料を安定化するための調製物及び方法
CN1105575C (zh) 冻干的干细胞因子制剂
Krishnamurthy et al. The stability factor: importance in formulation development
CN1155408C (zh) 冷冻干燥的稳定的单克隆或多克隆抗体药物制剂
CN1993138A (zh) 稳定蛋白质的方法
CN105816858B (zh) 重组vwf配方
CN1149283C (zh) 稳定谷氨酰胺转移酶制剂及其生产方法
CN1163288C (zh) 通过对流干燥法制造无定形产物的方法
JP2020143166A (ja) 凍結乾燥した組換え型ｖｗｆ製剤
CN1342087A (zh) 长期稳定的制剂
CN1756559A (zh) 稳定的含组织因子通路抑制剂或组织因子通路抑制剂变体的液体组合物
CN1181974A (zh) 低糖分、稳定的、不含白蛋的一种重组体凝血因子制剂
CN1628129A (zh) 蛋白质制剂的稳定化
JP2015098483A (ja) 第ｖｉｉｉ因子製剤
CN1261271A (zh) 多肽、蛋白和核酸的稳定的药用施用形式
CN1993139A (zh) 稳定的干扰素液体制剂
CN1481385A (zh) 制剂抗生素化合物的方法
CN1041799C (zh) 制备血栓溶解组合物的方法
CN1096222A (zh) 一种药物制剂
Lu et al. Solid State characterization of freeze-dried protein-excipient mixtures
HK1090284A (en) Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20031210

Termination date: 20111024